KYMR Stock Analysis: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$100.40
-3.00 (-2.90%)
▼
5d:
-8.77%
30d:
-11.55%
90d:
+24.4%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KYMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KYMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $100.40, which is considered oversold relative to its 30-day fair value range of $107.13 to $116.36.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is currently testing key support at $99.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $127.18 (+23.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is currently testing key support at $99.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $127.18 (+23.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$107.13 -
$116.36
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding KYMR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.0% below Wall St target ($127.18)
- CAUTION: Recommendation downgraded due to -8.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$107.13 -
$116.36
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$7.95
(7.9%)
Support & Resistance Levels
Support Level
$99.52
Resistance Level
$114.15
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.74
Wall Street Target
$127.18
(+23.0%)
Revenue Growth (YoY)
55.5%
Share & Embed Analysis
Last updated: August 03, 2026 1:47 PM ET
Data refreshes hourly during market hours. Next update: 2:47 PM
Data refreshes hourly during market hours. Next update: 2:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce Booth
SELL
5900 shares
2026-04-22
Jeremy G Chadwick
SELL
300 shares
2026-04-22
Bruce Booth
SELL
100 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 51 HOLD |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
